Monday, June 30, 2025 6/30/2025

The Golgi complex and HSV entry

Award Number: R03AI178458
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/05/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2026

Group Awards By:

View Award Description

The Golgi complex and HSV entry - Herpes simplex virus (HSV) causes lifelong latent infections in humans. It is responsible for significant disease, ranging from cold sores and genital infections to blindness and fatal encephalitis. There is no effective vaccine and no cure. The long-term objective of this project is a detailed understanding of the intracellular pathway taken by HSV entering during infection. The endocytosis pathway utilized by HSV during entry into human epithelial cells was identified 20 years ago. However, the specific vesicular compartments traversed by HSV during its journey to the nucleus are not known. We demonstrated that HSV does not travel the conventional lysosome-terminal endocytosis pathway during viral entry. Based on our previous results and new preliminary studies, we hypothesize that incoming HSV utilizes a retrograde transport pathway to the Golgi apparatus for successful entry into physiologically relevant cells. Completion of this pilot study will demonstrate that HSV transits the Golgi complex prior to arrival at the nucleus during successful entry. Our experimental design employs techniques of cell biology, biochemistry, microscopy, and molecular virology. Completing this study will establish critical features of the entry pathway taken by HSV in epithelial cells, the in vivo target of primary and recurrent infection. These studies will support the innovative concept that the Golgi complex and Golgi-related functions mediate HSV entry and will lay the foundation for identification of the intracellular site of HSV membrane fusion. Furthermore, the results will aid in the development of new preventions and therapeutics for HSV.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $76,500 )
2025	2025	WASHINGTON STATE UNIVERSITY	240 FRENCH ADMINISTRATION BLDG	PULLMAN	WA	99164	WHITMAN	USA	Allergy and Infectious Diseases Research	000	2	5/21/2025	NON-COMPETING CONTINUATION	$76,500
														Subtotal = $76,500

Issue Date FY: 2024 ( Subtotal = $76,500 )
2024	2024	WASHINGTON STATE UNIVERSITY	240 FRENCH ADMINISTRATION BLDG	PULLMAN	WA	99164	WHITMAN	USA	Allergy and Infectious Diseases Research	000	1	7/5/2024	NEW	$68,850
2024	2024	WASHINGTON STATE UNIVERSITY	240 FRENCH ADMINISTRATION BLDG	PULLMAN	WA	99164	WHITMAN	USA	Allergy and Infectious Diseases Research	001	1	9/11/2024	NEW	$7,650
														Subtotal = $76,500

Grand Total All Awards = $153,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Golgi complex and HSV entry

Award Number: R03AI178458

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/05/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer